A fast, simple, and cost-effective method of expanding patient-derived xenograft mouse models of pancreatic ductal adenocarcinoma

被引:6
|
作者
Liu, Zhenyang [1 ,2 ]
Ahn, Michael Ho-Young [1 ]
Kurokawa, Tomohiro [1 ]
Ly, Amy [3 ]
Zhang, Gong [1 ]
Wang, Fuyou [1 ]
Yamada, Teppei [1 ]
Sadagopan, Ananthan [1 ]
Cheng, Jane [1 ]
Ferrone, Cristina R. [1 ,4 ]
Liss, Andrew S. [4 ]
Honselmann, Kim C. [4 ]
Wojtkiewicz, Gregory R. [5 ]
Ferrone, Soldano [1 ,6 ]
Wang, Xinhui [1 ]
机构
[1] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Div Surg Oncol, Boston, MA 02115 USA
[2] Cent South Univ, Xiangya Sch Med, Hunan Canc Hosp, Dept Gastroenterol & Urol & Med Oncol, Changsha, Hunan, Peoples R China
[3] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA
[4] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Div Gen & Gastrointestinal Surg, Boston, MA 02115 USA
[5] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Syst Biol, Mouse Imaging Program, Boston, MA 02115 USA
[6] Harvard Med Sch, Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02115 USA
关键词
PDX expansion; Subcutaneous PDX mouse model; Orthotopic PDX mouse model; PDAC PDX; CANCER; TISSUE; PLATFORM; TRIAL;
D O I
10.1186/s12967-020-02414-9
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background Patient-derived xenograft (PDX) mouse models of cancer have been recognized as better mouse models that recapitulate the characteristics of original malignancies including preserved tumor heterogeneity, lineage hierarchy, and tumor microenvironment. However, common challenges of PDX models are the significant time required for tumor expansion, reduced tumor take rates, and higher costs. Here, we describe a fast, simple, and cost-effective method of expanding PDX of pancreatic ductal adenocarcinoma (PDAC) in mice. Methods We used two established frozen PDAC PDX tissues (derived from two different patients) and implanted them subcutaneously into SCID mice. After tissues reached 10-20 mm in diameter, we performed survival surgery on each mouse to harvest 90-95% of subcutaneous PDX (incomplete resection), allowing the remaining 5-10% of PDX to continue growing in the same mouse. Results We expanded three consecutive passages (P1, P2, and P3) of PDX in the same mouse. Comparing the times required for in vivo expansion, P2 and P3 (expanded through incomplete resection) grew 26-60% faster than P1. Moreover, such expanded PDX tissues were successfully implanted orthotopically into mouse pancreases. Within 20 weeks using only 14 mice, we generated sufficient PDX tissue for future implantation of 200 mice. Our histology study confirmed that the morphologies of cancer cells and stromal structures were similar across all three passages of subcutaneous PDX and the orthotopic PDX and were reflective of the original patient tumors. Conclusions Taking advantage of incomplete resection of tumors associated with high local recurrence, we established a fast method of PDAC PDX expansion in mice.
引用
下载
收藏
页数:12
相关论文
共 50 条
  • [21] A Comparative Study of Patient-Derived Tumor Models of Pancreatic Ductal Adenocarcinoma Involving Orthotopic Implantation
    Yanagihara, Kazuyoshi
    Iino, Yuki
    Yokozaki, Hiroshi
    Kubo, Takanori
    Oda, Tatsuya
    Kubo, Takashi
    Komatsu, Masayuki
    Sasaki, Hiroki
    Ichikawa, Hitoshi
    Kuwata, Takeshi
    Seyama, Toshio
    Ochiai, Atsushi
    PATHOBIOLOGY, 2022, 89 (04) : 222 - 232
  • [22] Generation and application of patient-derived xenograft models in pancreatic cancer research
    WangCheng-Fang
    ShiXian-Jie
    中华医学杂志(英文版), 2019, (22) : 2729 - 2730-2731-2732-2733-2734-2735-2736
  • [23] Generation and application of patient-derived xenograft models in pancreatic cancer research
    Wang, Cheng-Fang
    Shi, Xian-Jie
    CHINESE MEDICAL JOURNAL, 2019, 132 (22) : 2729 - 2736
  • [24] Molecular assessment of clinical antitumour therapeutics utilising established pancreatic ductal adenocarcinoma patient-derived models
    Suh, Y-A.
    ANNALS OF ONCOLOGY, 2023, 34 : S197 - S197
  • [25] Patient-derived xenograft models of BRCA-associated pancreatic cancers
    Golan, Talia
    Atias, Dikla
    Stossel, Chani
    Raitses-Gurevich, Maria
    ADVANCED DRUG DELIVERY REVIEWS, 2021, 171 : 257 - 265
  • [26] Decellularized patient-derived pancreatic ductal adenocarcinoma xenografts for tumour physicochemical characterization
    Garcia Gareta, Elena
    Gracia Costa, Carlos
    Enrique Guerrero, Pedro
    Alaman Diez, Pilar
    Rueda Flores, Ana
    Olivera Jurjo, Nerea
    Sancho, Patricia
    Angeles Perez, Maria
    Garcia Aznar, Jose Manuel
    TISSUE ENGINEERING PART A, 2023, 29 (13-14)
  • [27] APPROACH TO PRECISION MEDICINE FOR PANCREATIC DUCTAL ADENOCARCINOMA USING PATIENT-DERIVED ORGANOIDS
    Matsumoto, Kazuhide
    Fujimori, Nao
    Ohno, Akihisa
    Murakami, Masatoshi
    Teramatsu, Katsuhito
    Takeno, Ayumu
    Ueda, Keijiro
    Ogawa, Yoshihiro
    GASTROENTEROLOGY, 2023, 164 (06) : S772 - S772
  • [28] Identification of tumor microenvironment components in patient-derived pancreatic ductal adenocarcinoma organoids
    Gao, Mei
    Bailey, Charles J.
    Harper, Megan M.
    Cavnar, Michael J.
    Pandalai, Prakash
    Qasem, Shadi A.
    Kim, Joseph
    CANCER RESEARCH, 2022, 82 (10)
  • [29] Patient-derived tumor xenografts as pharmacological model of human pancreatic ductal adenocarcinoma
    Anastasia, Alessia
    Resovi, Andrea
    Ghilardi, Carmen
    Avigni, Roberta
    Micotti, Edoardo
    Minoli, Lucia
    Scanziani, Eugenio
    Corbellini, Carlo
    Morandi, Eugenio
    Belotti, Dorina
    Giavazzi, Raffaella
    Bani, MariaRosa
    CANCER RESEARCH, 2017, 77
  • [30] Use of patient-derived xenograft mouse models in cancer research and treatment
    Yada, Erica
    Wada, Satoshi
    Yoshida, Shintaro
    Sasada, Tetsuro
    FUTURE SCIENCE OA, 2018, 4 (03):